Document Detail

Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature.
MedLine Citation:
PMID:  20217448     Owner:  NLM     Status:  MEDLINE    
We report a case of renal tubular acidosis (RTA) secondary to capecitabine, oxaliplatin, and cetuximab administration in a 63-year-old woman with liver metastasis from colon carcinoma who had partial treatment response. On day 5 posttreatment, she arrived to the emergency room with severe weakness, and blood tests demonstrated hypokalemia with metabolic acidosis. Urine potassium levels were elevated, and the transtubular potassium gradient (TTKG) was 6.6, consistent with hypokalemic RTA with associated Fanconi syndrome, which presented as hyperphosphaturia, uricaciduria, and loss of protein and sugar in the urine. She was treated with intravenously administered potassium and fluids. RTA is one type of nephrotoxicity induced by chemotherapy, and it is reversible in mild cases when appropriately treated. The mechanism of RTA induced by chemotherapy in cancer patients has not yet been clearly elucidated. Oncologists should therefore be aware of the potential for RTA to occur after capecitabine, oxaliplatin, and cetuximab treatment, especially in the context of other predisposing factors.
Amir Sonnenblick; Amichay Meirovitz
Related Documents :
1302158 - Radiation-induced optic neuropathy.
2939108 - Dilantin-induced long-term bilateral total external ophthalmoplegia.
3973118 - Postoperative (pressure) alopecia.
10348328 - Asynchronous and asymmetric burst-suppression in a patient with a corpus callosum lesion.
19644538 - A case of recurrent multifocal central giant cell granulomas.
21309308 - Hazard report. ecri institute recommends reporting emi events.
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2010-03-10
Journal Detail:
Title:  International journal of clinical oncology     Volume:  15     ISSN:  1437-7772     ISO Abbreviation:  Int. J. Clin. Oncol.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-11     Completed Date:  2010-11-23     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  9616295     Medline TA:  Int J Clin Oncol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  420-2     Citation Subset:  IM    
Oncology Department, Hadassah-Hebrew University Medical Center, Ein Kerem, POB 12000, 91120 Jerusalem, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acidosis, Renal Tubular / chemically induced*,  therapy
Adenocarcinoma / drug therapy*,  secondary,  surgery
Antibodies, Monoclonal / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Chemotherapy, Adjuvant
Colonic Neoplasms / drug therapy*,  pathology,  surgery
Deoxycytidine / administration & dosage,  analogs & derivatives
Fluid Therapy
Fluorouracil / administration & dosage,  analogs & derivatives
Liver Neoplasms / drug therapy*,  secondary
Middle Aged
Organoplatinum Compounds / administration & dosage
Potassium / administration & dosage
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Organoplatinum Compounds; 51-21-8/Fluorouracil; 63121-00-6/oxaliplatin; 6804DJ8Z9U/capecitabine; 7440-09-7/Potassium; 951-77-9/Deoxycytidine; PQX0D8J21J/cetuximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or...
Next Document:  (18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts p...